Weightloss Medications Surge in Popularity Among UK Businesses

Weight-loss drugs have experienced a remarkable rise in the UK since their approval in 2023. As many as 1.5 million Britons are now reported to be using GLP-1 medications for weight loss, with an estimated three million additional individuals seeking prescriptions. This burgeoning interest has prompted significant changes in workplace healthcare offerings.

A recent survey conducted by Howden found that 44 per cent of employers with health care plans are contemplating the inclusion of weight-loss medications in their employee benefits. Major healthcare insurers, including Vitality and Bupa, have already begun offering discounts on drugs such as Wegovy and Mounjaro to corporate clients, with prominent firms like Deloitte taking advantage of these initiatives.

Vitality became a pioneer in the UK by introducing subsidised weight-loss medication within its healthcare packages. Employers engaged in this programme can provide their staff access to GLP-1 drugs if specific eligibility criteria are met, including a minimum body mass index for those aged 35 and older. Employees are also given access to a free GP consultation to determine their eligibility for the treatment.

Despite the advantages of these schemes, concerns surrounding the high costs of subsidising such medications persist. Bupa’s recent announcements indicated that prior to any discounts, the monthly costs of Wegovy can range from £169 to £239, while Mounjaro is priced between £199 and £360. The financial burden of providing these treatments poses a challenge for businesses as they consider implementing such benefits.

The increasing prevalence of obesity in the UK is a pressing health issue. With people living with obesity facing a higher rate of hospitalisation and lost productivity, employers know that addressing these concerns could yield positive outcomes for both staff and the organisation. Companies are under pressure to adapt employee benefits that effectively tackle this growing problem.

Yet, healthcare professionals have noted the need for substantial long-term support for those undergoing weight-loss treatment. Research indicates that while individuals can lose an average of a fifth of their body weight during treatment, many regain around 0.8 kg each month once they discontinue use. As such, employers may be wary of the long-term implications and potential liabilities associated with these medications.

As companies navigate the complexities of incorporating weight-loss medications into their healthcare plans, the landscape of employee benefits continues to evolve. The balance between meeting employee demand for health interventions and managing the financial implications remains a crucial challenge for many organisations.